ALLIANCEBERNSTEIN L.P. - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$342,584
-27.9%
30,670
+38.1%
0.00%
Q2 2023$475,294
-39.9%
22,210
+13.7%
0.00%
Q1 2023$790,198
-24.2%
19,540
-12.8%
0.00%
Q4 2022$1,042,746
-60.6%
22,415
-56.1%
0.00%
-100.0%
Q3 2022$2,647,000
-55.6%
51,029
-59.6%
0.00%
-66.7%
Q2 2022$5,966,000
-24.3%
126,204
+14.0%
0.00%0.0%
Q1 2022$7,882,000
+76.1%
110,729
+85.0%
0.00%
+50.0%
Q4 2021$4,476,000
+238.8%
59,854
+157.4%
0.00%
+100.0%
Q3 2021$1,321,000
+17.0%
23,250
-9.4%
0.00%
Q2 2021$1,129,000
-10.8%
25,6500.0%0.00%
-100.0%
Q1 2021$1,265,000
+17.6%
25,650
+0.3%
0.00%0.0%
Q4 2020$1,076,000
-8.1%
25,5700.0%0.00%0.0%
Q3 2020$1,171,000
-20.0%
25,570
-12.3%
0.00%0.0%
Q2 2020$1,463,000
-2.4%
29,1400.0%0.00%0.0%
Q1 2020$1,499,000
-16.7%
29,1400.0%0.00%0.0%
Q4 2019$1,800,000
-41.6%
29,140
-43.2%
0.00%
-50.0%
Q3 2019$3,082,000
-32.7%
51,300
-5.5%
0.00%
-33.3%
Q2 2019$4,582,000
+5.2%
54,300
+19.1%
0.00%0.0%
Q1 2019$4,356,000
+34.9%
45,6000.0%0.00%
+50.0%
Q4 2018$3,230,000
-13.8%
45,600
+4.0%
0.00%0.0%
Q3 2018$3,746,000
-21.8%
43,830
+6.0%
0.00%
-33.3%
Q2 2018$4,790,000
+68.1%
41,330
+17.3%
0.00%
+50.0%
Q1 2018$2,850,000
-41.0%
35,230
-57.2%
0.00%
-33.3%
Q4 2017$4,827,000
+12.0%
82,260
-10.7%
0.00%0.0%
Q3 2017$4,311,000
+71.6%
92,120
+31.9%
0.00%
+50.0%
Q2 2017$2,512,000
+7.4%
69,820
-8.0%
0.00%0.0%
Q1 2017$2,338,000
-47.2%
75,910
-42.5%
0.00%
-50.0%
Q4 2016$4,424,000
+21.7%
132,060
-3.3%
0.00%
+33.3%
Q3 2016$3,636,000
+151.5%
136,630
+108.4%
0.00%
+200.0%
Q2 2016$1,446,000
+71.3%
65,560
+128.0%
0.00%0.0%
Q1 2016$844,000
+6.3%
28,750
+19.6%
0.00%0.0%
Q4 2015$794,000
-6.7%
24,040
+2.1%
0.00%0.0%
Q3 2015$851,000
-19.9%
23,540
-0.3%
0.00%0.0%
Q2 2015$1,062,000
+142.5%
23,600
+65.0%
0.00%
Q1 2015$438,000
-16.4%
14,300
+38.8%
0.00%
Q4 2014$524,000
+28.4%
10,3000.0%0.00%
Q3 2014$408,000
+21.4%
10,300
+32.1%
0.00%
Q2 2014$336,000
+11100.0%
7,800
+10163.2%
0.00%
Q1 2014$3,000
+50.0%
760.0%0.00%
Q4 2013$2,000
-84.6%
76
-86.8%
0.00%
Q3 2013$13,000
-45.8%
576
-57.4%
0.00%
Q2 2013$24,0001,3520.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 858,811$36,156,00010.56%
Fairmount Funds Management LLC 150,433$6,333,0002.26%
ARMISTICE CAPITAL, LLC 1,356,000$57,088,0001.94%
FARALLON CAPITAL MANAGEMENT LLC 1,775,000$74,728,0000.45%
Virtus ETF Advisers LLC 14,321$603,0000.25%
Granahan Investment Management 231,071$9,728,0000.22%
JACOBS LEVY EQUITY MANAGEMENT, INC 248,320$10,454,0000.09%
ACADIAN ASSET MANAGEMENT LLC 467,514$19,684,0000.08%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 126$5,0000.08%
AIGEN INVESTMENT MANAGEMENT, LP 12,854$541,0000.07%
View complete list of ENANTA PHARMACEUTICALS INC shareholders